These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26524723)

  • 1. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Wheeler DT; Bristow RE; Kurman RJ
    Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.
    Arnett-Mansfield RL; deFazio A; Wain GV; Jaworski RC; Byth K; Mote PA; Clarke CL
    Cancer Res; 2001 Jun; 61(11):4576-82. PubMed ID: 11389093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
    Gallos ID; Devey J; Ganesan R; Gupta JK
    Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
    Baker J; Obermair A; Gebski V; Janda M
    Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
    Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
    BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells.
    Goto T; Takano M; Albergaria A; Briese J; Pomeranz KM; Cloke B; Fusi L; Feroze-Zaidi F; Maywald N; Sajin M; Dina RE; Ishihara O; Takeda S; Lam EW; Bamberger AM; Ghaem-Maghami S; Brosens JJ
    Oncogene; 2008 Jan; 27(1):9-19. PubMed ID: 17599040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response.
    Tierney KE; Ji L; Dralla SS; Yoo E; Yessaian A; Pham HQ; Roman L; Sposto R; Mhawech-Fauceglia P; Lin YG
    Gynecol Oncol; 2016 Dec; 143(3):650-654. PubMed ID: 27771165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
    Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
    Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
    Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
    J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.